G1 Therapeutics Inc (NAS:GTHX)
$ 7.15 0 (0%) Market Cap: 377.22 Mil Enterprise Value: 364.45 Mil PE Ratio: 0 PB Ratio: 15.31 GF Score: 31/100

G1 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 07:50PM GMT
Release Date Price: $19.52 (-2.20%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome everyone to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.

Our next presenting company is G1 Therapeutics. And speaking on behalf of the company, we have CEO, Jack Bailey. (Operator Instructions)

With that, I will pass it over to Jack.

John E. Bailey
G1 Therapeutics, Inc. - CEO, President & Director

Thank you, Anupam. I'm especially excited to be presenting today because G1 Therapeutics stands on the cusp of our first FDA product approval and launch for our lead therapy, trilaciclib. I will share with you today why we are confident we will be successful with this initial indication and how it represents the first step in what we believe is a much larger opportunity for trilaciclib across multiple tumor types going forward.

On Slide 2, given I'll be making forward-looking statements, obviously, normal safe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot